Vivus, Inc.: VVUS (NASDAQ)
WWW.VIVUS.COM
VIVUS Product Pipeline Update 7/18/2002
During the second quarter of 2002, the Company continued
recruitment for its at-home study to evaluate the safety and efficacy
of ALISTA(TM), used in the home setting for the treatment of female
sexual arousal disorder. The study is a placebo-controlled,
double-blind trial being conducted at multiple sites throughout the
United States. Recruitment continues and the study is progressing
well.
Data from a single dose efficacy and safety in-clinic study of
ALISTA was presented at the Annual Meeting of the American Urological
Association in Orlando, Florida in May. Additionally, the Company has
been selected to present its results from a study entitled, "Use of
Standardized Visual Sexual Stimulations (VSS) for in-Clinic Evaluation
of Pharmacologic Treatment of Female Sexual Arousal Disorder," at the
Western Sectional American Urological Association Meeting in Kauai, HI
this October.
The Company also initiated a clinical trial to evaluate the safety
and efficacy of TA-1790, a fast acting, highly selective, potent oral
phosphodiesterase type 5 (PDE5) inhibitor, in men with ED. The study
is a multi-center, double-blind, placebo-controlled evaluation of
TA-1790 using Rigiscan(TM) to assess the erectile response. At this
time, patient enrollment is approximately 80% complete and we are on
track to conclude the trial by the fourth quarter of 2002.
The Company has completed a pharmacokinetic study with VI-0134,
its oral on-demand treatment for premature ejaculation. In June, VIVUS
was awarded its fourth patent in the field of premature ejaculation
entitled, "Administration of Phosphodiesterase Inhibitors for the
Treatment of Premature Ejaculation." In addition, the Company will
evaluate its strategic options for the development of VI-0134 and
TA-1790 for premature ejaculation, pending the results of the ongoing
Rigiscan study.
About VIVUS
VIVUS, Inc. is a pharmaceutical company engaged in the development
of innovative therapies for the treatment of quality-of-life disorders
in men and women, with a focus on sexual dysfunction. Current
development programs target Female Sexual Dysfunction (FSD), Erectile
Dysfunction (ED) and Premature Ejaculation (PE). The Company developed
and markets in the U.S. MUSE(R) (alprostadil) and ACTIS(R), two
innovations in the treatment of erectile dysfunction, and has
partnered with Abbott Laboratories (NYSE:ABT) for the international
marketing and distribution of its male transurethral ED products. In
Canada, VIVUS has partnered exclusively with Paladin Labs (TSE:PLB) to
market and distribute MUSE. |
